Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury

• Status: Terminated
• Trial end date: 2021-02-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the hypothesis that isosorbide mononitrate prevents deterioration of renal function in patients receiving anti-angiogenic therapies that target vascular endothelial growth factor (VEGF).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Collaborator: National Kidney Foundation
• Treatments: Endothelial Growth Factors; Isosorbide; Isosorbide Dinitrate; Isosorbide-5-mononitrate; Mitogens

Criteria

Inclusion Criteria:

• Patients on or enrolled for anti-VEGF therapy

• new-onset proteinuria, defined as a urine protein: creatinine ratio (UPC) of >500mg/g or hypertension (Systolic BP ≥ 140 mm Hg and/or diastolic BP ≥ 90 mm Hg) or a decrease in eGFR by ≥ 25% from baseline before starting therapy.

Exclusion Criteria:

• Pregnant women

• Breast-feeding women.